UBS Maintains Buy on Immunovant, Raises Price Target to $56
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Colin Bristow has reaffirmed a Buy rating on Immunovant (NASDAQ:IMVT) and increased the price target from $55 to $56, indicating a positive outlook on the company's stock.
December 01, 2023 | 6:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Colin Bristow maintains a Buy rating on Immunovant and raises the price target from $55 to $56, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst like Colin Bristow from UBS typically signals a positive forecast for the company's stock, which can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100